Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
28.85
+0.99 (3.55%)
Oct 8, 2025, 2:10 PM EDT - Market open
Maze Therapeutics Employees
Maze Therapeutics had 125 employees as of December 31, 2024.
Employees
125
Change
n/a
Growth
n/a
Revenue / Employee
$20,000
Profits / Employee
-$590,384
Market Cap
1.27B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 125 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MAZE News
- 2 days ago - Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - GlobeNewsWire
- 26 days ago - Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript) - Seeking Alpha
- 27 days ago - Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential - Benzinga
- 27 days ago - Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement - GlobeNewsWire
- 27 days ago - Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) - GlobeNewsWire
- 5 weeks ago - Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry - GlobeNewsWire
- 2 months ago - Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - GlobeNewsWire